Birger Lindberg Møller , is a professor in Plant Biochemistry at the University of Copenhagen (UCPH) (since 1984) and also Director of the Carlsberg Laboratory (since 2014).
He holds a Ph.D. and a D.Sc. from UCPH). He is Head of the VILLUM research center “Plant Plasticity” and of the synthetic biology center “bioSYNergy” funded by the UCPH Excellence Program for Interdisciplinary Research. He was a founder of the biotech company Poalis A/S which was subsequently acquired by Evolva A/S. His research interests are elucidation of the biosynthesis and function of bio-active natural products in plants with focus on cyanogenic glucosides, vanillin and terpenoids. Reactions catalyzed by cytochrome P450 enzymes are of special interest. Synthetic biology approaches have been used to build a platform for light driven synthesis of high value terpenoids.
Jay Keasling, co-founder of a number of startups in this space, including Amyris (NASDAQ: AMRS), one of the most recognised names in commercial synthetic biology.
He is a professor in the Department of Chemical & Biomolecular Engineering and the Department of Bioengineering, Senior Faculty Scientist and Associate Laboratory Director for Biosciences at Lawrence Berkeley National Laboratory, and Chief Executive Officer of the Joint BioEnergy Institute. The Keasling group is perhaps best known for its contributions to the development of a synthetic biology technique for producing the anti-malaria treatment artemisinin in yeast — at a fraction of the cost of plantation-derived artemisinin.
Jörg Bohlmann, Professor and Distinguished University Scholar at the University of British Columbia, Vancouver, Canada. .
He is a professor at UBC in the Michael Smith Laboratories, the Department of Botany, the Department of Forest and Conservation Sciences, Associate in the UBC Wine Research Centre, co-Director of the UBC Genome Sciences and Technology (GSAT) Graduate Program, and has been a Project Leader of five large-scale, Genome Canada-funded genomics projects in plant genomics and synthetic biology. The Bohlmann lab (www.michaelsmith.ubc.ca/faculty/bohlmann/) is internationally recognized for its program in plant genomics and terpenoid secondary metabolism.
Karl-Heinz Altmann, ETH Zürich.
Prof. Karl-Heinz Altmann studied chemistry at the University of Mainz, Germany, and he holds a Ph. D. in organic chemistry from the University of Basel, Switzerland. Since 2003 he is Full Professor of Pharmaceutical Sciences at the Swiss Federal Institute of Technology (ETH) in Zürich, Switzerland. Before 2003, he had spent 13 years in drug discovery research at Novartis Pharma, where he was the Senior Scientific Expert for Chemistry (2000- 2002) and the acting Global Head of Discovery Chemistry (2003). Prof. Altmann’s research interests are at the interface between chemistry and biology, with a particular focus on the chemical synthesis of biologically active natural products and their synthetic and semi-synthetic analogs.
Karsten Kristiansen, Head of Department of Biology, University of Copenhagen.
Karsten Kristiansen is Professor of Molecular Biology and Head of the Department of Biology, University of Copenhagen. He was previously Professor at the Department of Biochemistry and Molecular Biology, University of Southern Denmark, where he was head of department from 1992 to 2005. He was a co-founder of BioLigands ApS and served as CEO from 2002-2007. After graduation from the University of Copenhagen, he held postdoctoral positions at the Max-Planck-Institut für Molekulare Genetik in Berlin and at the Institut de Biologie Physico-Chimique, Fondation Edmond de Rothschild, in Paris. He is member of the Danish Academy of Natural Sciences and visiting professor at the Beijing Genomics Institute. His research focuses on regulation of gene expression and cellular differentiation with particular emphasis on lipid signalling and the effects of natural compounds.
Vincent Martin , Canada Research Chair in Microbial Genomics and Engineering, Professor in the Department of Biology and Co-Director of the Centre for Applied Synthetic Biology Concordia University.
Vincent Martin is a Professor in the Department of Biology at Concordia University and holds the Canada Research Chair in Microbial Genomics and Engineering. He is a co-founder of Amyris Inc as well as a co-founder and co-director of the Concordia Centre for Applied Synthetic Biology. From 2009 to 2014, professor Martin co-lead the Genome Canada PhytoMetaSyn project aimed at developing synthetic biosystems for the production of high-value plant metabolites. His research interests focus on the combined power of genomics and metabolic engineering for the biological synthesis of industrial chemicals and natural products. He holds a BSc and PhD in Microbiology from McGill University and the University of British Columbia, respectively.